UCLA receives $9.1M from NCI to improve early detection

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH.

An opportunity for Trump: Position U.S. cancer science to lead the world

Last November, the American public voted on America First causes, which include the greatest scientific discovery and achievement enterprise in the world: The National Institutes of Health. NIH has made America first in biomedical science for the past century.

Shorter radiation therapy after prostate surgery safe, UCLA study finds

For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence.

May 16, 2025

Vol.51 No.19

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

How is the enterprise of cancer research doing after the first 100 days of the Trump administration?

May 09, 2025

Vol.51 No.18

By Paul Goldberg and Jacquelyn Cobb

Cancer Policy

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Over $180 million in NCI grants have been terminated between Feb. 28 and April 8, according to a systematic review published in JAMA May 8.

May 09, 2025

Vol.51 No.18

By Jacquelyn Cobb

UCLA receives $9.1M from NCI to improve early detection

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

An opportunity for Trump: Position U.S. cancer science to lead the world

Shorter radiation therapy after prostate surgery safe, UCLA study finds

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Renew today!

Subscriber content

Never miss an issue!

Login

UCLA receives $9.1M from NCI to improve early detection

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

An opportunity for Trump: Position U.S. cancer science to lead the world

Shorter radiation therapy after prostate surgery safe, UCLA study finds

Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit